Literature DB >> 3182793

Mutant human adenosine deaminase alleles and their expression by transfection into fibroblasts.

A L Akeson1, D A Wiginton, M R Dusing, J C States, J J Hutton.   

Abstract

Adenosine deaminase (ADA) deficiency in humans is one cause of severe combined immunodeficiency disease. Single base mutations affecting the ADA protein have been identified for both alleles of the ADA-deficient cell line GM2606 and for one allele of the ADA-deficient cell line GM2825A. One allele of GM2606 has a mutation altering amino acid 101 from Arg to Trp, and the other allele has a mutation altering amino acid 211 from Arg to His. As previously reported, one ADA allele of GM2825A has a single base mutation changing Ala-329 to Val-329, and the other allele has a mutation which eliminates exon 4 from the mature mRNA. Sequence analysis of polymerase chain reaction-amplified GM2825A DNA showed a single base change of A to G within the invariant bases of the 3' splice site of intron 3 that can account for the mis-splicing of exon 4. To test the effect on ADA catalytic activity of these mutations and the mutations previously found in the ADA-deficient line GM2756, expression vectors containing normal and mutant ADA-coding sequences under transcriptional regulation of the Rous sarcoma virus long terminal repeat were constructed and transfected into human fibroblasts. All transfected cells had levels of ADA mRNA 15-25 times higher than the endogenous ADA message. Yet, cells transfected with the normal ADA-coding sequences had ADA enzymatic levels 40 times higher than cells transfected with any of the mutant ADA sequences. This analysis demonstrates that while the mutant ADA-coding sequences are transcribed, they do not encode a functional ADA protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182793

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses.

Authors:  B A Conlon; W R Law
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

Review 2.  Prospects for homologous recombination in human gene therapy.

Authors:  M A Vega
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

Review 3.  Application of the polymerase chain reaction to the diagnosis of human genetic disease.

Authors:  J Reiss; D N Cooper
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

4.  Homozygosity for a newly identified missense mutation in a patient with very severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).

Authors:  R Hirschhorn; V Chakravarti; J Puck; S D Douglas
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

5.  Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.

Authors:  Renata Baffelli; Lucia D Notarangelo; Luisa Imberti; Michael S Hershfield; Federico Serana; Ines Santisteban; Federica Bolda; Fulvio Porta; Arnalda Lanfranchi
Journal:  J Clin Immunol       Date:  2015-09-16       Impact factor: 8.317

6.  Hot spot mutations in adenosine deaminase deficiency.

Authors:  R Hirschhorn; S Tzall; A Ellenbogen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  Nature and frequency of mutations in the argininosuccinate synthetase gene that cause classical citrullinemia.

Authors:  K Kobayashi; H Kakinoki; T Fukushige; N Shaheen; H Terazono; T Saheki
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

8.  Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype.

Authors:  I Santisteban; F X Arredondo-Vega; S Kelly; A Mary; A Fischer; D S Hummell; A Lawton; R U Sorensen; E R Stiehm; L Uribe
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery.

Authors:  R Hirschhorn; D R Yang; A Israni; M L Huie; D R Ownby
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

10.  A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution.

Authors:  M L Markert; C Norby-Slycord; F E Ward
Journal:  Am J Hum Genet       Date:  1989-09       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.